India’s national list of essential medicines 2022 features 34 additions, including insulin glargine, teneligliptin, lenalidomide, bedaquiline and montelukast, with price control expected to follow on these drugs.

GSK has poached its new chief financial officer from fashion brand Burberry, but Julie Brown’s experience at AstraZeneca and Roche will give her insights into how to lead GSK into its next phase.

Leading the company with the only therapy approved for NTM lung disease, Will Lewis tells In Vivo that success comes from giving researchers room to breath, visualizing patient benefit, and sailing into uncharted waters.

Building a narrow set of products and services that provide reliable and consistent revenue is a perfectly sound business strategy and one that sustains many biotech companies. But for the hungrier, like Twist Biosciences, Inc., a strategy of ongoing disruption and evolution has been more appealing and indeed is generating significant growth. Emily Leproust, Twist’s CEO, spoke with In Vivo about what it means to follow a value-added business strategy.